Aigen Investment Management’s Vir Biotechnology VIR Stock Holding History

Aigen Investment Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,249	Closed	-$181K	–	812
2026 Q1	$181K	Buy	20,249 +7,614	+60%	+$60.7K	0.05%	437
2025 Q4	$76.2K	Buy	+12,635	New	+$75.2K	0.02%	523
2025 Q2	–	Sell	-17,155	Closed	-$111K	–	1088
2025 Q1	$111K	Buy	+17,155	New	+$153K	0.02%	683
2024 Q3	–	Sell	-19,224	Closed	-$171K	–	1034
2024 Q2	$171K	Buy	+19,224	New	+$184K	0.03%	640
2023 Q4	–	Sell	-19,427	Closed	-$182K	–	1110
2023 Q3	$182K	Buy	+19,427	New	+$277K	0.03%	688
2022 Q1	–	Sell	-9,174	Closed	-$418K	–	1112
2021 Q4	$418K	Buy	+9,174	New	+$359K	0.03%	685

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Aigen Investment Management's VIR Position: Q2 2026 in Review

Aigen Investment Management sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 20,249 shares — an estimated $181K sold.

Aigen Investment Management first reported a position in VIR in Q4 2021 and held it in 6 quarters. The position peaked at $418K in Q4 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Aigen Investment Management reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
Aigen Investment Management sold 20,249 Vir Biotechnology shares in Q2 2026, an estimated $181K.
Aigen Investment Management first reported a position in Vir Biotechnology in Q4 2021 and held it in 6 quarters.
Aigen Investment Management's Vir Biotechnology position peaked at $418K in Q4 2021.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.